P21

10mg Vial

2 September 2026Updated 2 September 2026

P21

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for P21.

Create free account Member login

Full range of benefits for P21

May support tissue repair and wound healing (in vitro/animal studies)

May enhance cell migration and proliferation during regeneration

May modulate inflammatory signaling to limit chronic inflammation

May promote angiogenesis and microvascular remodeling

May influence collagen deposition and extracellular matrix remodeling

May exert neuroprotective effects in preclinical neuronal models

May regulate immune cell chemotaxis and local immune responses

May affect matrix metalloproteinase activity during tissue repair

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 20 known interactions

Synergistic(5)Compatible(5)Monitor(5)Avoid(5)

Generally well-tolerated alongside this peptide

Metformin

Common insulin-sensitizing therapy with no known direct pharmacodynamic conflict with P21 and generally requires no adjustment.

Statins (e.g., atorvastatin)

Lipid-lowering agents that have no demonstrated direct interaction with P21 and are typically safe to continue.

ACE inhibitors (e.g., enalapril)

Antihypertensive therapy that is pharmacologically compatible with P21 without routine dose modification.

Topical antibiotics (e.g., mupirocin)

Localized antimicrobial therapy for skin infections is generally compatible with systemic P21 administration.

Proton pump inhibitors (e.g., omeprazole)

Gastroprotective acid suppression is unlikely to affect the systemic actions of P21 and typically requires no special precautions.

All interaction categories

Synergistic (5)

Somatropin (recombinant human growth hormone): Co-administration may amplify anabolic and tissue-repair effects because both agents promote cellular proliferation and matrix synthesis.
Mecasermin (recombinant IGF-1): Concurrent IGF-1 signaling can potentiate regenerative and anabolic responses, enhancing overall tissue recovery.
Sildenafil (PDE5 inhibitor): Augmented local blood flow from PDE5 inhibition may enhance angiogenesis and delivery to injured tissues, complementing P21's reparative actions.
Omega-3 fatty acids (EPA/DHA): Anti-inflammatory effects of omega-3s can create a favorable milieu for P21-mediated healing and reduce excessive inflammatory interference.
Vitamin D3 (cholecalciferol): Vitamin D supports musculoskeletal and bone remodeling processes, potentially synergizing with P21-driven repair mechanisms.

Compatible (5)

Metformin: Common insulin-sensitizing therapy with no known direct pharmacodynamic conflict with P21 and generally requires no adjustment.
Statins (e.g., atorvastatin): Lipid-lowering agents that have no demonstrated direct interaction with P21 and are typically safe to continue.
ACE inhibitors (e.g., enalapril): Antihypertensive therapy that is pharmacologically compatible with P21 without routine dose modification.
Topical antibiotics (e.g., mupirocin): Localized antimicrobial therapy for skin infections is generally compatible with systemic P21 administration.
Proton pump inhibitors (e.g., omeprazole): Gastroprotective acid suppression is unlikely to affect the systemic actions of P21 and typically requires no special precautions.

Monitor (5)

Warfarin: Monitor INR because changes in inflammation, healing, or hepatic function associated with P21 could alter warfarin metabolism and bleeding risk.
Direct oral anticoagulants (apixaban, rivaroxaban): Monitor for bleeding and clinical signs of hemorrhage as interactions affecting vascular integrity or healing could increase bleeding risk.
Insulin and oral hypoglycemics: Monitor blood glucose and adjust antihyperglycemic dosing as P21 may modify insulin sensitivity or systemic metabolic demands.
Immunosuppressants (tacrolimus, cyclosporine): Monitor drug levels and immune function because P21's immunomodulatory effects could necessitate dose adjustments to maintain therapeutic immunosuppression.
Systemic corticosteroids (prednisone): Monitor wound healing and clinical response because corticosteroids can blunt repair and may require coordination of dosing with P21 therapy.

Avoid (5)

Active malignancy or recent cancer therapy: Exercise caution because P21's pro-proliferative and regenerative effects could theoretically promote tumor growth or interfere with oncologic treatments.
Pregnancy and breastfeeding: Avoid or carefully evaluate use due to insufficient safety data and potential risk to fetal or neonatal development.
Severe hepatic impairment: Use caution because altered peptide clearance or coexisting coagulopathy may increase risk of adverse effects or accumulation.
Autoimmune diseases (e.g., uncontrolled systemic lupus erythematosus): Caution is warranted because immune modulation from P21 could exacerbate underlying autoimmune activity or change disease course.
EGFR inhibitors (oncology agents): Exercise caution as opposing effects on epithelial repair and wound healing may increase skin and mucosal adverse events or impair recovery.